-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195

Benzinga·08/10/2026 17:53:15
语音播报
Truist Securities analyst Danielle Brill reiterates Insmed (NASDAQ:INSM) with a Buy and raises the price target from $185 to $195.